Metrics Files Patent for Controlled-Release System
Metrics Files Patent for Controlled-Release System
Scientists at Metrics, Inc. (Greenville, NC) have developed an extended-release drug delivery platform for tablets requiring zero-order or near-zero–order in vitro dissolution.
According to Metrics's development scientist Brian Woodall, the delivery system is based on a unique ratio of FDA-approved, National Formulary-grade excipients as well as a minor thin-film coating (3–5%). The technology, currently the subject of a provisional patent application, is similar to a matrix tablet system in that it depends on the behavior of the selected polymers to swell, dissolve, and form a gel-like mass at a specific rate, which enables a controlled and steady release. The film coating prevents initial dose-dumping when the tablet is dropped into a dissolution vessel, thereby extending the release rate. The manufacture of the system involves dry-blending the active ingredient, compressing the tablet, and applying the film coating.
Woodall and co-developer Brad Gold, Metrics's director of pharmaceutical development and new technologies, report the delivery mechanism is pH-independent, suitable for both low and relatively high-dose active ingredients, as well as for water-soluble and -insoluble compounds that are hydrophobic or hydrophilic. The company plans to present more information about the technology at the American Association of Pharmaceutical Scientists annual meeting in November.
–Maribel Rios
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
